IMMULITE 2000 PSA
Siemens Healthcare Diagnostics, Inc. · Decision date Jul 27, 2026
What did the FDA decide?
FDA records P930027/S039 as a supplement to PMA P930027, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 27, 2026.
FDA approval order statement
Approval of the change to in-process manufacturing quality testing for the IMMULITE 2000 XPi analyzers and IMMULITE 2000 / IMMULITE 2000 XPi spare probe assemblies.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Jul 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P930027/S039
- Regulatory pathway
- PMA supplement
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTF
- Decision code
- OK30
- Decision date
- Jul 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P930027. Subsequent supplements may change the device or its indications.
FDA decision timeline
P930027 · Original PMA
IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS
P930027/S036 · Related supplement
IMMULITE 2000 Prostate-Specific Antigen (PSA)
P930027/S037 · Related supplement
IMMULITE 2000 PSA
P930027/S038 · Related supplement
IMMULITE 2000 PSA
P930027/S039 received
Application receipt date recorded by FDA.
P930027/S039 · FDA decision
30-Day Notice
P930027/S040 · Related supplement
IMMULITE Systems PSA
P930027/S041 · Related supplement
IMMULITE Systems PSA
Timeline entries are records held by MedtechLedger for P930027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P930027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Siemens Healthcare Diagnostics, Inc. | PMA approval | Sep 15, 1995 | FDA | |
IMMULITE 2000 Prostate-Specific Antigen (PSA)P930027/S036 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 14, 2025 | FDA |
IMMULITE 2000 PSAP930027/S037 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 30, 2025 | FDA |
IMMULITE 2000 PSAP930027/S038 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
IMMULITE Systems PSAP930027/S040 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE Systems PSAP930027/S041 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MTF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Atellica IM Total PSA II (tPSAII)P240021/S001 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 26, 2026 | FDA |
| Roche Diagnostics Corp. | PMA supplement | Apr 29, 2026 | FDA | |
Elecsys total PSA assayP990056/S045 | Roche Diagnostics Corp. | PMA supplement | Feb 27, 2026 | FDA |
| ABBOTT LABORATORIES | PMA supplement | Feb 23, 2026 | FDA | |
| ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- Glyn Rhonwy, Llanberis, Gwynedd Ll55 4el, LL554EL
Sources and methodology
- Original FDA record: P930027/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





